Viral phenotype and fitness

New Microbiologica

Volumn 27, Issue 2 SUPPL. 1, 2004, Pages 71-76

  Andreoni, M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

HIV fitness; Viral phenotype; Viral replicative capacity

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

CONFERENCE PAPER; DISEASE COURSE; DRUG SENSITIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION; RNA VIRUS; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ADAPTATION, BIOLOGICAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 11844294671     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. BACK, N.K., NIJHUIS, M., KEULEN, W., BOUCHER, C.A., OUDE ESSINK, B.O., VAN KUILENBURG, A.B., VAN GENNIP, A.M., BERKHOUT, B. (1996). Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J, 15, 4040-4049.
2. BERKHOUT B. (1999) HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J Biomed Sci, 6, 298-305.
3. BLEIBER, G., MUNOZ, M., CIUFFI, A., MEYLAN, P., TELENTI, A. (2001). Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug- resistant human immunodeficiency virus type 1. J Virol, 75, 3291-3300.
4. BORMAN, A.M., PAULOUS, S., CLAVEL, F. (1996). Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. Journal of General Virology, 77, 419-426.
5. BRENNER, B., PETRELLA, M., SPIRA, B., ROUTY, J., WAINBERG, M.A. Persistence of multidrug resistant HIV-1 with diminished fitness acquired in primary infection. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 2001.
6. BURKE D.S. (1997). Recombination in HIV: an important viral evolutionary strategy. Emerging Infectious Diseases, 3, 1-9.
7. CLAVEL, F., RACE, .E, MAMMANO, F. (2000) HIV drug resistance and viral fitness. Adv Pharmacol, 49, 41-66.
8. COFFIN, J.M. (1995). HIV population dynamics in vivo: implications for genetic variation,pathogenesis, and therapy. Science, 267: 483-489.
9. CROTEAU, G., DOYON, L., THIBEAULT, D., MCKERCHER, G., PILOTE, L., LAMARRE, D. (1997). Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol, 71, 1089-1096.
10. CROTEAU, G., DOYON, L., THIBEAULT, D., MCKERCHER, G., PILOTE, L., LAMARRE, D. (1997) Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors, J Virol, 71, 1089-1096.
11. DEEKS, S.G., WRIN, T., LIEGLER, T., HOH, R., HAYDEN, M., BARBOUR, J.D., HELLMANN, N.S., PETROPOULOS, CJ, MCCUNE, JM, HELLERSTEIN, MK, GRANT, RM. (2001). Virologic and immunologic consequences of discontinuing combination antiretroviral - drug therapy in HIV-infected patients with detectable viremia. N Engl J Med, 344, 472-480.
12. DEVEREUX, H.L., EMERY, V.C., JOHNSON, M.A., LOVEDAY, C. (2001). Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol, 65, 218-224.
13. DOMINGO, E., ESCARMIS, C., MENENDEZ-ARIAS, L., HOLLAND, J. (1999). Viral quasispecies and fitness variations. In: Domingo E, Webster R, Holland J, editors. Origin and evolution of viruses. San Diego: Academic Press, 141-161.
14. DOMINGO, E., HOLLAND, J.J. (1997). RNA virus mutations and fitness for survival. Annu Rev Microbiol, 51, 151-178.
15. EASTMAN, P.S., MITTLER, J., KELSO, R., GEE, C., BOYER, E., KOLBERG, J., URDEA, M., LEONARD, J.M., NORBECK, D.W., MO, H., MARKOWITZ, M. (1998). Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol, 72, 5154-5164.
16. EIGEN M. (1993). Viral quasispecies. Sci Am, 269, 4249.
17. ESTE, J.A, QUINONES-MATEU, M.E, BARRETINA, J., ARMAND-UGON, M., SCHOLS, D., BLANCO, J., GUTIERREZ, A., CLOTET, B., DE CLERCQ, E. Reduced fitness of HIV-1 that are resistant to CXCR4 antagonists due to alterations in gp120 function. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, Scottsdale, Arizona June 2001.
18. FENYO, E.M., ALBERT, J., ASJÖ, B. (1989). Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS, 3, S5-12.
19. FROST, S.D., NIJHUIS, M., SCHUURMAN, R., BOUCHER, C.A., BROWN, A.J. (2000). Evolution of lamivudine resistance in human immunodeficiency virus type 1- infected individuals: the relative roles of drift and selection. J Virol, 74, 6262-6268.
20. GOTTE, M., ARION, D., PARNIAK, M.A., WAINBERG, M.A. (2000). The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol, 74, 3579-3585.
21. GOUDSMIT, J., DE RONDE, A., DE ROOIJ, E., DE BOER, R. (1997) Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol, 71, 4479-4484.
22. HAHN, B.H., SHAW, G.M., DE COCK, K.M., SHARP, P.M. (2000). AIDS as a zoonosis: scientific and public health implications. Science, 287, 607-614.
23. HO, D.D., NEUMANN, A.U., PERELSON, A.S., CHEN, W., LEONARD, J.M., MARKOWITZ, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373, 123-126.
24. HOLLAND, J.J., DE LA TORRE, J.C., CLARKE, D.K., DUARTE, E. (1991). Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J Virol, 65, 2960-2967.
25. IGLESIAS-USSEL, M.D., CASADO, C., YUSTE, E., OLIVARES, I., LOPEZ-GALINDEZ, C. (2002). In vitro analysis of HIV-1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol, 83, 93-101.
26. LITTLE, S.J., DAAR, E.S., D'AQUILA, R.T., KEISER, P.H., CONNICK, E., WHITCOMB, J.M., HELLMANN, N.S., PETROPOULOS, C.J., SUTTON, L., PITT, J.A., ROSENBERG, E.S., KOUP, R.A., WALKER, B.D., RICHMAN, D.D. (1999). Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA, 282, 1142-1149.
27. MAEDA, Y., VENZON, D.J., MITSUYA, H. (1998). Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi- dideoxynucleoside resistance. J Infect Dis, 177, 1207-1213.
28. MANSKY, L.M., TEMIN, H.M. (1995). Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol, 69, 5087-5094.
29. MILLER, V. (2001) International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr, 26, S34-S50.
30. NIJHUIS, M., DEEKS, S., BOUCHER, C. (2001). Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis, 14:23-28.
31. PANDEY, V.N., KAUSHIK, N., REGE, N., SARAFIANOS S.G., YADAV P.N., MODAK M.J. (1996). Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry, 35, 2168-2179.
32. PRESTON, B.D., DOUGHERTY J.P. (1996). Mechanisms of retroviral mutation. Trends in Microbiology, 4, 16-21.
33. PUIG, T., PEREZ-OLMEDA, M., RUBIO, A., RUIZ, L., BRIONES, C., FRANCO J.M., GOMEZ-CANO, M., STUYVER, L., ZAMORA, L., ALVAREZ, C., LEAL, M., CLOTET, B., SORIANO, V. (2000). Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS, 14, 727-732.
34. QUINONES-MATEU, M.E., ARTS, E.J. (1999). Recombination in HIV-1: Update and implications. AIDS Reviews, 1, 89-100.
35. QUINONES-MATEU, M.E., TADELE, M., PARERA, M., MAS, A., CLOTET, B., DOMINGO, E., MENENDEZ-ARIAS, L., MARTINEZ, M.A. Decreased viral fitness conferred by a multidrug-resistant HIV-1 reverse transcriptase harbouring a dipeptide insertion between codons 69 and 70. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, Scottsdale, Arizona June 2001.
36. RICHMAN, D.D. Two unrelated studies from 1 lab: HIV drug resistance in the US and decay of latency. 2nd HIV DRP Symposium Antiviral Drug Resistance, Chantilly, Virginia December 2001.
37. SAAG, M.S., HAHN, B.H., GIBBONS, J., LI, Y., PARKS, E.S., PARKS, W.P., SHAW, G.M. (1988). Extensive variation of human immunodeficiency virus type-1 in vivo. Nature, 334, 440-444.
38. SHAFER, R.W., DUPNIK, K., WINTERS, M.A., ESHLEMAN, S.H. A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. HIV Sequence Compendium 2000.
39. SHAFER R.W., DUPNIK K., WINTERS M.A, ESHLEMAN S.H. A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. HIV Sequence Compendium 2000.
40. WEBER, J., VALDEZ, H., RANGEL, H.R., CHAKRABORTY, B., CONNICK, E., SMITH, K., LANDAY, A., KURITZKES, D.R., LEDERMAN, M.M., QUINONES-MATEU, M.E. (2002). A pilot study to analyze HIV-1 fitness evolution under a protease inhibitor-based therapy shows a diverse response depending of the basal genotypic context of the virus. 9th Conference on Retroviruses and Opportunistic Infections, Seattle.
41. WEI, X., GHOSH, S.K., TAYLOR, M.E., JOHNSON, V.A., EMINI, E.A., DEUTSCH, P., LIFSON, J.D., BONHOEFFER, S., NOWAK, M.A., HAHN, B.H., SAAG, M.S., SHAW, G.M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 373, 117-122.
42. th International Workshop on HIV Drug Resistance & Treatment Strategies, Scottsdale, Arizona June 2001.